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1900. Last year national health care costs rose 10%. Health care providersand third-party payers are under increasing pressure to reduce costsyet maintain or even improve quality. So can adding an additionaltest, such as positron emission tomography (PET), to an alreadyexpensive evaluation, such as lung cancer assessment, reduce costand improve quality? It could, if it reduces unnecessary tests and
surgery and accurately directs treatment.
Simply, PET is expensive. The high quality, 3-dimensional reconstruction capa-
bility, in-computer software systems cost $1.5 to $2.0 million; computed tomogra-
phy combined systems PET/CT are more than $2.0 million (Sue Ann Halliday,
ImageMed Group, LLC, and Barry Siegel, Washington University, St Louis, Mo,
personal communications). To provide appropriate space in most medical centers
costs an additional $1.5 to $2.0 million. The radiopharmaceutical contrast is also
expensive. For the study of lung cancer, most centers use fluorodeoxyglucose F 18
(FDG). It has a brief shelf life, the half-life being 110 minutes. For in-house
production, a cyclotron is used that costs $1.0 to $2.0 million. A practical alterna-
tive, purchase of commercially made FDG, is approximately $300 to $450 per dose.
Thus the initial cost for a complete in-house system is $4 to $6 million dollars. This
total does not include the costs of the technicians, part- or full-time physicists,
nurses, and nuclear radiologists appropriately trained to run, operate, and maintain
the equipment and to read the resultant images. The per-study cost for an ear lobes
to pelvis single-patient study in most medical centers is $2800 to $3500, nearly 7
times the cost of a chest/upper abdominal computed tomogram.
The use of PET and the conclusions we make are dependent on two assumptions.
First, staging matters. Identifying the state of biologic progression or stage to
determine the prognosis and management is important to success in treatment.
Second, ideally selected treatment can improve survival and reduce the hindrance of
the disease, ultimately reducing the cost of care. Presumably PET should help to
discriminate patients who have limited disease, those most effectively treated with
surgery.
Generally and not to be completely inclusive, we have learned a number of things
about the use of FDG-PET in the clinical evaluation of lung cancer:
1. It is useful in diagnosis and staging,1 though it neither diagnoses nor excludes
the presence of malignancy.
2. It can discriminate less suitable candidates for surgical resection, estimated to
be 20% to 25% of potential surgical patients.2-4
3. It may provide helpful prognostic information in additional to the staging
information.5-7
In medical centers that wish to provide complete and accurate staging for their
patients and who do not have an accomplished surgeon who can perform medias-
tinoscopy or thoracoscopy, is PET an alternative to a thoracic surgical investigation?
When reviewing clinical PET research, we must make sure that we understand
the differences among the studies. First, the machines used for positron acquisition
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have different capabilities. Older and cheaper versions have
lower sensitivities. Although reported as PET studies, some
studies have not used PET technology at all, instead using
coincidence gamma scanning systems. Second, the ma-
chines are not truly objective. Interpretation is variable.
With greater training and experience, the PET reader devel-
ops greater accuracy. Third, the contrast medium in most
cases, FDG, has a short half-life, and thus the timing of
injection, absorption, and data acquisition may make a
difference in the results. Fourth, patient populations differ.
Most studies are performed at tertiary care centers and may
not represent a generalizable study population. Not all study
patients are known to have lung cancer or suspected lung
cancer. Some studies exclude patients for a variety of dif-
ferent medical conditions, such as diabetes, or for other
individual characteristics. The prevalence of mediastinal
cancer varies greatly, with some as low as 5% to 10%, and
because of the low sample size it is difficulty to define
mediastinal staging accuracy. Fifth, studies differ in how
they determine the presence of malignancy in the primary
lesion, the hilar or mediastinal nodes, or in the metastases.
Some use cytologic examination or follow-up to determine
presence of cancer, an option inferior to histologic biopsy.
Sixth, the PET interpreters may or many not be aware of the
pathologic data. Knowing whether a mass or a node is
positive at the time the PET scan is reviewed may influence
the result, making the study results less helpful. Seventh,
prospective trials are necessary to decrease selection bias
and improve our understanding of the modality in question.
Finally, many of the studies differ in how they deal with
hyperglycemia. Performing FDG-PET on a hyperglycemic
patient may dramatically alter the PET result, making it less
likely to identify malignancy. In light of all these differ-
ences, we should carefully interpret the PET literature,
especially when applying the information to our patients.
When it comes to the mediastinum, most studies that
were performed before 2000 had relatively few patients who
had mediastinal cancer or had undergone thorough histo-
logic biopsy, yet conclusions were made about the accuracy
of the PET.8 Because of this, the research results and
conclusions are likely less accurate, and the small sample
size results in an inordinately large confidence interval. Poor
patient selection, surgical technique, and different PET
scanning technology make the results less generalizable.
Most studies had fewer than 100 patients. Now with larger
trials, some prospective, we can provide helpful information
to our colleagues. The technique used to prove the presence
of cancer has been variable: observation, bronchoscopy
fine-needle aspiration (FNA), computed tomography–di-
rected FNA, computed tomography–directed core needle
biopsy, mediastinoscopy–directed FNA, and histologic bi-
opsy by mediastinoscopy, thoracoscopy, or thoracotomy.
The success of each technique varies with the skills and
experience of the professional performing the biopsy and
the location of the lesion or metastasis or node. Also, the
statistical techniques were variable. Some counted each
node group separately; thus an individual tumor or patient
could be overexpressed in the results, resulting in bias. This
is difficult, because PET findings rely upon the degree of
radioactivity expressed relative to the surrounding area of
interest, and nodes or masses adjacent to a particularly
high-intensity structure, such as the heart or liver, or to
known tumor may be inappropriately regarded as negative
for metastases because of the overshadowing effect of the
emission system. We must carefully review the various
results obtained to see whether they apply to our patients or
research question.
In this issue, Gonzalez-Stawinski and colleagues9 from
Duke University report a 5-year analysis of 202 patients
with known or suspected lung cancer who underwent PET
scanning before mediastinoscopy, 22% of whom had patho-
logically demonstrable disease. Their primary objective was
to compare results of the Duke PET scanning system with
those of histologic samples obtained by mediastinoscopy
and thoracotomy. Duke is superbly suited to comment on
the use of PET in the evaluation of lung cancer patients. It
has a long history of PET research, the latest machinery, and
highly qualified PET readers, along with exceptional tho-
racic surgeons and a large patient population from which to
draw study participants. Rather than FNA frequently used in
previous studies, only histologic tissue samples from medi-
astinoscopy were compared with the PET results. The me-
diastinum was evaluated on the PET scans by visual anal-
ysis; no attempt was made at software-corrected objectivity
such as by using a standard uptake value. The PET readers
were blinded to the histologic results. In addition, and what
is particularly unique about this trial, they tested their results
beyond the traditional pathologic findings by following up
their patients for an additional 1 to 2 years to see whether
the patients had mediastinal recurrence or died of their
disease. No one was unavailable for follow-up. Also
uniquely, they assessed the mediastinum as a whole; indi-
vidual nodes or stations were not separately assessed. Not
attempting to unfairly stretch PET technology, the Duke
investigators simply asked the question of whether the me-
diastinum was positive or negative; either by PET, medias-
tinoscopy, or long-term follow-up. The particularly helpful
part of their final results was their finding of 64.4% sensi-
tivity, 77.1% specificity, 44.6% positive predictive value,
and 88.3% negative predictive value of PET in the medias-
tinum.
Their results are similar to my own group’s results at the
University of Iowa10 in a similar patient population, a trial
size of 237 and 24% with mediastinal disease. We found
sensitivity of 68%, specificity of 82%, positive predictive
value of 54%, and negative predictive value of 89%. The
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results in the two studies are similar. The Duke investigators
have concluded, as we did, that relative to mediastinoscopy
PET alone is not sufficient to accurately stage the medias-
tinum and that mediastinoscopy should continue to be per-
formed in potentially operable cases. Like ourselves, they
found that PET improved the accuracy of mediastinoscopy.
Unlike the Iowa study, they analyzed their mediastinoscopy
results with the thoracotomy nodal assessment and followed
up their patients with positive PET results but negative
pathologic results. Nine of the 32 patients had recurrence
within the 2-year follow-up, but none had recurrence in the
mediastinum.
There are some inherent problems with the Duke proto-
col, as with ours:
1. PET centers and PET machines are likely to have
different results from Duke. We should expect that at
less experienced centers with less expensive PET
scanners the positive predictive value and negative
predictive value will be worse. Perhaps improved soft-
ware, better PET machines, and newer contrast media
may significantly improve the ability of PET to stage
the mediastinum, but with current technology it does
not do the job.
2. Only PET data were used to assess the prediction. No
information about the patient, computed tomographic
data (such as size, location, border, evidence of inva-
sion), other PET data (such as the standard uptake
value of the primary, disease elsewhere in the patient,
or the standard uptake value was used to predict dis-
ease in the mediastinum), or any other clinical results
such as information from other scans or tests were
included in the analysis. If this information were
added to the PET information, it might enhance the
prediction of mediastinal cancer.
3. The Duke team’s assessment of the mediastinum as a
whole is not sufficient for our staging needs. The issue
of whether the contralateral or multinodal station dis-
ease is very relevant to prognosis and treatment deci-
sions. To be comparable, PET must be able to analyze
mediastinal node stations, not necessarily individual
nodes, to stage the mediastinum.
4. An inherent problem of the FDG contrast is that in-
flamed tissues will absorb it. Institutions with a high
prevalence of granulomatous or inflammatory medi-
astinal disease or cases of obstructive malignant pro-
cesses may have difficulty identifying mediastinal ma-
lignancy with PET.
5. For us to make a global statement about the ability of
PET to stage, we are excluding a number of patients
from the analysis pool, such as those with tracheosto-
mies or uncontrolled diabetes; PET may be worse or
better by including these additional patients.
6. Surgeons use the PET results to perform their medi-
astinoscopy, and thus PET may fare better than me-
diastinoscopy alone. In the Duke and Iowa studies,
PET was not compared with mediastinoscopy alone
but with PET plus mediastinoscopy.
7. Pathologic sampling may not be sufficiently accurate
to assess involvement of mediastinal nodes.
In a seemingly similar article, different results were
reported by Vesselle and colleagues11 from the University
of Washington in September 2002. The University of Wash-
ington group retrospectively evaluated their patients with
non–small cell lung cancer (NSCLC) who had undergone
PET scanning and mediastinoscopy. Relative to the Duke
and Iowa studies, the University of Washington group
showed that PET scanning was significantly more accurate.
The accuracy was 90.7%, sensitivity was 80.9%, specificity
was 96%, positive predictive value was 91.9%, and negative
predictive value was 90.1%. The questions asked by this
group were not about the accuracy of PET staging of the
mediastinum. Their primary objective was to evaluate the
contribution of PET to the staging of lung cancer in their
patients. As a secondary finding, they identified the accu-
racy of staging the mediastinum. Their study was different
from the Duke and Iowa studies. The University of Wash-
ington study selected only patients that had a diagnosis of
lung cancer, eliminating those with other diagnoses. They
eliminated those with primary lesions that were less than 1
cm and eliminated cases that did not appear to have signif-
icant nodal pathology according to computed tomography.
By doing so, they selected out a group of patients that might
have greater PET accuracy. Like the Duke and Iowa Stud-
ies, they too found that the PET was helpful at directing the
mediastinoscope for biopsy. However, their subselection
does not represent the group of patients seeing a thoracic
surgeon for resection. The Duke and Iowa studies represent
typical patients who would be seen by a thoracic surgeon.
Two meta-analyses have been performed on the subject
of the accuracy of FDG-PET to stage the mediastinum.12,13
At first glance, one might review the large tables from these
reviews and, on the basis of their significant cumulative
sample sizes, incorrectly conclude that PET accurately
stages the mediastinum. This research technique fails from
selection bias of the research trials included in the analysis
and by the fact that newer techniques or technologies may
not be included at the time of the meta-analyses publication.
One of the studies, that of Toloza and colleagues, 13 re-
quired the publications to have more than 20 patients, pub-
lication in a peer-reviewed journal, cytologic examination
as admissible, and the availability of raw data for analyses.
From the data, receiver operating characteristic analysis was
performed on the studies, but no attempt was made to
determine whether the science of the research trials was
sound and usable. Dwamena and associates12 made every
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effort to perform a complete worldwide analysis of the
literature at the time of their publication in 1999. They
included only studies in which third-generation scanners or
higher were used, patients fasted for at least 4 hours, the
interpretation protocol was described, PET interpreters were
blinded, there was histologic sampling only, results were
reported in sufficient detail for the creation of contingency
tables, and established PET criteria were used for the de-
termination of the presence or absence of malignancy. They
did not exclude studies in which the primary intent of the
study was something other than determining the accuracy of
FDG-PET in the mediastinum, the trial appeared to be
retrospective, nodal stations or the entire mediastinum were
assessed rather than individual nodes, or there were clear
criteria for how certain circumstances were accommodated,
such as diabetes and tracheostomy. As a result, the conclu-
sions from these meta-analyses too are suspect, and repeated
analyses attempting to objectively assess ability of PET to
stage the mediastinum may find relatively few articles that
possess the qualities necessary to draw helpful conclusions
to determine the role of FDG-PET in the evaluation of the
patient with NSCLC. The Duke and Iowa articles possess
these criteria and have discovered the same results.
Current FDG-PET technology alone does not appear to
be sufficient to warrant reliable treatment changes or the
avoidance of mediastinoscopy. It is unlikely that the addi-
tion of transbronchial, transtracheal, and endoscopic ultra-
sonographically guided FNA will sufficiently rule out dis-
ease relative to the histologic results achieved from
mediastinoscopy. However, PET may improve the accuracy
of mediastinoscopy, allowing the mediastinoscopist to di-
rect a more thorough biopsy of areas that appear suspect on
PET.
It appears that we have added yet another test, and a very
expensive one, to the already expensive evaluation of the
patient with lung cancer. From the contributions of the Duke
and Iowa articles, we cannot eliminate mediastinoscopy in
the staging of NSCLS. Seemingly we are increasing the
expense, but FDG-PET has helped to discriminate patients
with nonsurgically treatable disease and directing them to
nonsurgical intervention earlier in the course of their dis-
ease, potentially reducing costs and complications while
improving outcomes. As the Duke group states in their
discussion, we will need to assess the economic impact of
this finding. Perhaps with newer PET technology or possi-
bly an alternative tracer, improved software, improved tech-
nique of performing PET, and inclusion of additional clin-
ical information, we may be able to exclude
mediastinoscopy altogether, at least in a subset of patients.
To date we cannot exclude mediastinoscopy in the evalua-
tion of the patient with NSCLC.
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